

091-196432

For Internal Use Only	Submit 1 Original	OMB Approval No.:
Sec File No. 91 -	and 9 Copies	Expires:

Estimated average burden hours per response: 2.00

RECEIVED
2015 DEC -8 PM 3:30
SEC / YR

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 19b-4(e)**

**Information Required of a Self-Regulatory Organization Listing and Trading a New
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934**

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I Initial Listing Report

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:

NYSE Arca, Inc.

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):

Open-end Management Investment Company

SEC
Mail Processing
Section
DEC 08 2015

3. Class of New Derivative Securities Product:

Investment Company Units

Washington DC
404

4. Name of Underlying Instrument:

S&P Biotechnology Select Industry Index

5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:

Narrow-Based



6. Ticker Symbol(s) of New Derivative Securities Product:

LABS

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:

NYSE, NASDAQ

8. Settlement Methodology of New Derivative Securities Product:

Regular way trades settle on T+3/Book entry only held in DTC.

9. Position Limits of New Derivative Securities Product (if applicable):

Not applicable.

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:

Martha Redding

Title:

Senior Counsel and Assistant Secretary

Telephone Number:

(212) 656-2938

Manual Signature of Official Responsible for Form:

December 4, 2015
SEC 2449 (1/99)

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	DEC 08 2015



Martha Redding
Senior Counsel
Assistant Secretary

New York Stock Exchange
11 Wall Street
New York, NY 10005
T + 1 212 656 2938
F + 1 212 656 8101
Martha.Redding@theice.com

Via Overnight Mail

December 4, 2015

Ms. Gail Jackson
US Securities and Exchange Commission
Division of Trading and Markets
Station Place -- Building I
100 F Street, N.E. -- Room 6628
Washington, DC 20549

SEC
Mail Processing
Section
DEC 08 2015
Washington DC
401

Re: 19b-4(e) -- Transmittal

Dear Ms. Jackson:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find an original and nine copies of Form 19b-4(e) with respect to the securities listed below.

- Deutsche X-trackers MSCI All China Equity ETF (CN)
- SPDR S&P 500 Fossil Fuel Free ETF (SPYX)
- MomentumShares U.S. Quantitative Momentum ETF (QMOM)
- Direxion Daily Healthcare Bear 3X Shares (SICK)
- Direxion Daily Natural Gas 3X Shares (GASX)
- Direxion Daily S&P Biotech Bear 1X Shares (LABS)
- SPDR Russell 1000 Yield Focus ETF (ONEY)
- SPDR Russell 1000 Momentum Focus ETF (ONEO)
- SPDR Russell 1000 Low Volatility Focus ETF (ONEV)

If you have any questions, please do not hesitate to call me at (212) 656-2938.

Sincerely,


Enclosures

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	DEC 08 2015